Status:
COMPLETED
Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm
Lead Sponsor:
University of California, Irvine
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammat...
Eligibility Criteria
Inclusion
- Age ≥18 with a diagnosis of a Philadelphia chromosome negative Myeloproliferative Neoplasm (MPN) including Essential Thrombocythemia (ET), Polycythemia Vera (PV), or Myelofibrosis (MF)
- Has access to the internet and email
- MPN-Total Symptom Score (MPN-TSS) score of ≥10 on screening survey
- Mediterranean Adherence score of ≤10 on screening survey
- English fluency (intervention requires conversations with study staff)
- In the opinion of the study team is amenable to changing one's diet
Exclusion
- Pregnant or planning to become pregnant over the course of the study
- Has food allergies, intolerances, or other dietary restrictions which would severely limit changes to their diet toward a Mediterranean style diet (such as allergies to ALL tree nuts or olive oil)
Key Trial Info
Start Date :
January 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2021
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04744974
Start Date
January 21 2021
End Date
December 6 2021
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine
Irvine, California, United States, 92617